All In Biotech

Drug Trial Radar · NCT07354503

Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis

The Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis: A Multicenter Clinical Study

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational research design. It aims to compare the efficacy of Telitacicept with that of glucocorticoids, thereby providing clinicians with a reference for the rational and standardized application of Telitacicept.

Conditions

  • IgAVN
  • IgA Vasculitis

Interventions

  • Collect clinical data from the patients.Device

    This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions.

  • This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventionsDrug

    This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete remission rate of urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment
  2. The rate of change in urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment
  3. The rate of change in urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.